Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (242)	7/10/2001 12:11:44 PM
From: tuck	Read Replies (1) of 1005

BLUE Heaven: >>NEW YORK, July 10 (Reuters) - Robertson Stephens said Tuesday it started coverage of InterMune Inc. (NasdaqNM:ITMN - news) with a buy rating and a $55 price target. Biotechnology analyst Steven Harr estimated that the Brisbane, California-based company will lose $1.79 per share this year and lose $2.34 per share in 2002. ``InterMune has three marketed products, an estimated compounded annual revenue growth rate of 95 percent through 2006, and strong profitability in 2004 and beyond,'' Harr wrote in a research note. ``We believe the company has the potential to evolve into a large-cap biotechnology company with compelling earnings growth rate and returns on equity,'' he added. Shares rose 27 cents to $37.57 Tuesday on Nasdaq. << snip Sooo close to my $29 target just a little while ago. Argh. Edit: Speaking of BLUE Heaven, ARNA seems to be headed towards limbo. Anyone here follow ARNA or have a take on their research premium? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next